title: Risks of treatments and long-term outcomes of systemic ANCA-associated vasculitis.
abstract: Patients with ANCA-associated vasculitis (AAV) have an increased risk of premature death and organ failure. Treatment strategies with immune-suppressive drugs need to balance disease control and prevention of relapse against the risk of side effects in particular infection and malignancy. The longer-term outcome of patients with AAV who participated in several randomised controlled trials has been published in recent years. The results of these and other newer studies will be the focus of this review.
authors.affiliation: Royal Berkshire Hospital, Department of Nephrology, London Road, Reading, Berkshire, RG15AN, United Kingdom. Electronic address: oflossmann@doctors.org.uk.
authors.forename: Oliver
authors.initials: O
authors.lastname: Flossmann
mesh_terms: D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000150:complications / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000209:etiology; D004198:Disease Susceptibility; D005500:Follow-Up Studies; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000209:etiology; D015337:Multicenter Studies as Topic; D009369:Neoplasms / Q000209:etiology; D009894:Opportunistic Infections / Q000209:etiology; D011379:Prognosis; D011658:Pulmonary Fibrosis / Q000209:etiology; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012306:Risk; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents